Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 200 Results

Title
Intervention Indication Therapeutic Area Year Actions
Atezolizumab with chemotherapy for treating recurrent triple-negative breast cancer Atezolizumab (Tecentriq; MPDL3280A) , Chemotherapy Breast cancer Breast Cancer 2022 View  |  Download
Atezolizumab with platinum-based chemotherapy and bevacizumab for epithelial ovarian cancer or fallopian tube cancer or primary peritoneal cancer Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) , Chemotherapy Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2022 View  |  Download
Atogepant for prevention of migraine Atogepant (AGN-241689; MK-8031) Migraine Neurology 2022 View  |  Download
Bardoxolone Methyl for the treatment of chronic kidney disease (CKD) caused by Alport Syndrome Bardoxolone Methyl Alport Syndrome , Chronic kidney disease (CKD) Genetic Disorders , Nephrology 2022 View  |  Download
Baricitinib for treating atopic dermatitis in children and adolescents Baricitinib (LY3009104; Olumiant) Atopic dermatitis Dermatology 2022 View  |  Download
Baricitinib for treating juvenile idiopathic arthritis in paediatric patients Baricitinib (LY3009104; Olumiant) Juvenile psoriatic arthritis Rheumatology 2022 View  |  Download
Belantamab mafodotin for treating relapsed or refractory multiple myeloma Belantamab mafodotin (GSK2857916; anti-BCMA-ADC) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Belantamab mafodotin with bortezomib and dexamethasone for previously treated relapsed/refractory multiple myeloma Belantamab mafodotin (GSK2857916; anti-BCMA-ADC) , Bortezomib (Velcade; bortezomib mannitol boronic ester) , Dexamethasone (dexamethasone sodium metasulfobenzoate) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Belantamab mafodotin with pomalidomide and dexamethasone for previously treated relapsed/refractory multiple myeloma Belantamab mafodotin (GSK2857916; anti-BCMA-ADC) , Dexamethasone (dexamethasone sodium metasulfobenzoate) , Pomalidomide (Imnovid; CC-4047; Pomalyst) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Belimumab (subcutaneous injection) add-on for systemic lupus erythematosus in children aged 5 to 17 years old Belimumab (Benlysta; Lymphostat-B) Systemic lupus erythematosus (SLE) Immunology , Nephrology 2022 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications